Format

Send to

Choose Destination
J Infect. 2020 Mar 11. pii: S0163-4453(20)30113-4. doi: 10.1016/j.jinf.2020.03.002. [Epub ahead of print]

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.

Author information

1
Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.
2
Cancer Center, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
3
Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China. Electronic address: hongzhs@mail.sysu.edu.cn.
4
Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China. Electronic address: xiajinyu@mail.sysu.edu.cn.

Abstract

BACKGROUND:

Corona Virus Disease 2019 (COVID-19) due to the 2019 novel coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China. We aimed to compare arbidol and lopinavir/ritonavir(LPV/r) treatment for patients with COVID-19 with LPV/r only.

METHODS:

In this retrospective cohort study, we included adults (age≥18years) with laboratory-confirmed COVID-19 without Invasive ventilation, diagnosed between Jan 17, 2020, and Feb 13, 2020. Patients, diagnosed after Jan 17, 2020, were given oral arbidol and LPV/r in the combination group and oral LPV/r only in the monotherapy group for 5-21 days. The primary endpoint was a negative conversion rate of coronavirus from the date of COVID-19 diagnosis(day7, day14), and assessed whether the pneumonia was progressing or improving by chest CT (day7).

RESULTS:

We analyzed 16 patients who received oral arbidol and LPV/r in the combination group and 17 who oral LPV/r only in the monotherapy group, and both initiated after diagnosis. Baseline clinical, laboratory, and chest CT characteristics were similar between groups. The SARS-CoV-2 could not be detected for 12(75%) of 16 patients' nasopharyngeal specimens in the combination group after seven days, compared with 6 (35%) of 17 in the monotherapy group (p < 0·05). After 14 days, 15 (94%) of 16 and 9 (52·9%) of 17, respectively, SARS-CoV-2 could not be detected (p < 0·05). The chest CT scans were improving for 11(69%) of 16 patients in the combination group after seven days, compared with 5(29%) of 17 in the monotherapy group (p < 0·05).

CONCLUSION:

In patients with COVID-19, the apparent favorable clinical response with arbidol and LPV/r supports further LPV/r only.

KEYWORDS:

Antiviral intervention; Arbidol; Combination therapy; Corona Virus Disease 2019; Lopinavir/ritonavir

PMID:
32171872
DOI:
10.1016/j.jinf.2020.03.002

Conflict of interest statement

Declaration of Competing Interest The authors declare no conflict of interest.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center